Tipifarnib in Recurrent, Metastatic HRAS-Mutant Salivary Gland Cancer

BACKGROUND: To the authors’ knowledge, there are no approved therapies for recurrent, metastatic (R/M) salivary gland carcinoma (SGC), but molecularly targeted therapies warrant ongoing investigation. In the current study, the authors have reported on the efficacy of tipifarnib in patients with aggr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Hanna, Glenn J., Guenette, Jeffrey P., Chau, Nicole G., Sayehli, Cyrus M., Wilhelm, Christian, Metcalf, Robert, Wong, Deborah J., Brose, Marcia, Razaq, Mohammad, Pérez-Ruiz, Elisabeth, Cohen, Ezra E. W., Aggarwal, Rahul, Scholz, Catherine, Gualberto, Antonio, Ho, Alan L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8266417/
https://ncbi.nlm.nih.gov/pubmed/32557577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33036
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados